Charlotte's Web Urges Congress to Replace Section 781 Hemp Ban
The hemp CBD pioneer is asking lawmakers to swap Section 781's sweeping restrictions for enforceable standards that target delta-8 THC and protect children.

A detailed close-up of cannabis buds in a jar with a joint on a wooden surface.
Charlotte's Web puts its weight behind a regulatory framework, not a ban
The hemp CBD company said Congress should regulate intoxicating hemp products rather than restrict the category wholesale.
Charlotte's Web, one of the best-known names in hemp-derived CBD, urged lawmakers on Nov. 19, 2026 to drop the sweeping hemp restrictions in Section 781 and adopt a bipartisan framework in their place. Cannabis Business Times first reported the announcement.
According to the company, the replacement should do three things. It should protect children. It should eliminate synthetic and restricted intoxicating products such as delta-8 THC. And it should preserve consumer access to therapeutic hemp products.
Who's making the pitch is what stands out. A legacy CBD operator isn't defending the intoxicating-hemp market. It wants Congress to cut that segment out and spare everything else.
What Section 781 does, and what the signal doesn't say
Charlotte's Web describes Section 781 as a sweeping set of hemp restrictions, but the company's statement doesn't detail the provision's text.
The source material characterizes the section only in broad terms. It doesn't specify the vehicle the section sits in, the sponsors behind it, or the committee of jurisdiction. Readers tracking the language should consult the legislative text directly before drawing conclusions about its scope.
The company's position does make the framing of the fight clear. Section 781 is being treated as a blunt instrument, and Charlotte's Web wants a scalpel.
That distinction matters for the broader federal hemp loophole debate, which has pitted intoxicating-product critics against operators who sell non-intoxicating wellness goods under the same federal hemp definition.
Why a CBD incumbent wants delta-8 gone
Targeting synthetic intoxicants lets established hemp brands separate themselves from the products driving the regulatory backlash.
Delta-8 THC and similar converted cannabinoids have become the lightning rod for state and federal scrutiny. They sit outside the licensed adult-use markets in states like California and Ohio, often with little age gating or testing oversight.
For a CBD-focused company, that's a reputational and commercial problem. Broad restrictions written to stop delta-8 can also sweep up full-spectrum CBD, tinctures, and topicals, so Charlotte's Web is effectively arguing that precision protects its category.
Smart positioning. Backing tough standards on intoxicants is easy to defend on Capitol Hill, and it casts the company as a constructive voice rather than a lobbyist for the status quo.
What operators and patients should watch
The outcome will decide whether non-intoxicating hemp products keep a clear federal lane or get caught in a catch-all restriction.
The company's stated priorities map to concrete questions that any final language will have to answer:
- How lawmakers define and treat synthetic or converted cannabinoids
- What age-gating and child-protection requirements apply at retail and online
- Whether enforcement standards are specific enough to be workable for compliant sellers
- Whether therapeutic hemp products, including CBD, retain interstate access
Operators selling compliant products face the biggest swing in outcomes. A framework with clear testing and labeling rules could favor established brands, while a blunt restriction could strand inventory and shrink a category that survived the 2018 Farm Bill era on regulatory ambiguity.
The Charlotte's Web statement doesn't name co-sponsors or a vote schedule, so the legislative path remains unclear from the available source material. It's not a bill yet. It's a positioning move ahead of one.
Watch next for whether lawmakers publish replacement language for Section 781, and whether other hemp trade groups line up behind this approach or split from it.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws

Companies Warn New DEA Policy Imperils Medical Marijuana Markets
Law360 reports that cannabis companies say a new DEA policy threatens state medical marijuana markets, though the underlying policy text was not available to CannIntel.

Texas Gov.-elect Hinojosa favors repealing 'Death Star bill'
Houston Public Media reports Gina Hinojosa backs repeal of the so-called 'Death Star bill,' a stance that could reshape Texas hemp and THC policy if she acts on it.

Wicomico grower asks county for zoning change on indoor cannabis
A cultivator is seeking a text amendment in Wicomico County, Maryland, that would allow indoor cannabis growing, putting the county's zoning code in front of a local-control test.
More from the newsroom

California cannabis sales rebound a year after tax hike repeal
More than a year after lawmakers killed a short-lived excise increase, California retail sales are climbing again, but the recovery leaves a harder question about how much ground the state lost.

Grand Rapids Scraps Municipal Dispensary Build, Eyes Lease
The northern Minnesota city abandoned plans to construct its own cannabis storefront and will pursue leased space, according to KAXE.

Mile High Labs Files Type II DMF #044151 With FDA for CBD Isolate
The Loveland, Colo., ingredient maker opened a confidential FDA regulatory file on its CBD isolate, a supply-chain credential aimed at pharmaceutical buyers.